Storyline
Merck to acquire Terns Pharmaceuticals for $6.7 billion to gain promising leukemia drug
Merck has agreed to acquire Terns Pharmaceuticals in a $6.7 billion all-cash deal that secures a promising treatment for chronic myeloid leukemia (CML). The drug is positioned to compete with Novartis' established therapy Scemblix.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- BioPharma Divebiopharmadive.com
- Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset t...Fierce Biotech
- MSD rumoured to be nearing $6bn play for Terns Pharmapharmaphorum